Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Ocugen Stock Quote

Ocugen (NASDAQ: OCGN)

$1.32
(-8.3%)
-$0.12
Price as of April 18, 2024, 4:00 p.m. ET

Ocugen Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
OCGN +51.36% -88.66% -35.27% -54%
S&P +20.62% +72.50% +11.51% +68%

Ocugen Company Info

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

News & Analysis

The Fool has written over 200 articles on Ocugen.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.